pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Research on orexin and narcolepsy earns Lasker Award for Yanagisawa and Mignot

Sep 9, 2026·read at Endpoints ↗Positive

Masashi Yanagisawa and Emmanuel Mignot were honored with the Lasker Award for their work uncovering the role of orexin in narcolepsy. The award was announced on September 9, 2026.

Their research began with informal discussions in the lab and progressed through studies in mice and dogs, eventually involving the flu virus to deepen understanding of the disorder.

The findings have already been recognized with a Breakthrough Prize, highlighting the impact of this work on sleep‑disorder science and potential therapeutic approaches.

The Lasker Award underscores the importance of basic research in translating biological insights into future treatments for narcolepsy and related conditions.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Key research behind orexin and narcolepsy wins Lasker Award”

read at Endpoints ↗
91 words · retrieved 50m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PATH2Vyome Holdings, Inc

related stories

  • May 12Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Canceronclive
  • May 12Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugBioPharma Dive
  • May 12Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Riskonclive
  • May 11CSL sinks to nine-year low on revenue warning, $5B write-downEndpoints
  • May 11Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapiesBioPharma Dive